Dr. Thomas Paul Director of Cancer Epigenetics, Pfizer, USA2 Talks
Thomas Paul is Director of the Cancer Epigenetics Group in the Pfizer Oncology R&D unit in La Jolla, CA. His group focuses on therapeutic targeting of oncogenic gene expression pathways in cancer through pharmacological inhibition of epigenetic enzyme complexes. His group has progressed two compounds into clinical testing: PF-06821497 (EZH2... read moreinhibitor) and PF-06939999 (PRMT5 inhibitor).
Prior to joining Pfizer, Dr. Paul was a Scientist at Celgene in San Diego, CA (2009-2012) and was responsible for drug development activities for projects targeting epigenetic proteins including histone methyltransferases, histone demethylases, and histone readers.
He received his BS degree in Biology from the University of North Carolina at Chapel Hill in 1998 and his PhD from Cornell University in 2005 studying biochemistry. He was a postdoctoral fellow at the National Cancer Institute in Bethesda, MD from 2005-2009 where he studied cancer epigenetics in acute myeloid leukemia in the laboratory of Drs. Linda Wolff and Doug Lowy.